Neuromodulation is one of the fastest growing sectors of the medical device market. Neuromodulation is a rapidly evolving medical technique that provides symptomatic relief through the alteration, or modulation, of nerve system function. It works by either stimulating nerves to produce a natural biological response or by applying small doses of pharmaceutical agents directly to the site of action.
The market has significant potential for growth with the increasing global burden of neurological and cardiovascular disorders, especially in the emerging economies. The growth in emerging markets such as India and China will be driven by an aging population that will increase demand for newer treatment options for age-related diseases. India’s expanding economy is likely to see an increased wealth among the population, specifically within the middle class, which will cause an increased adoption of westernised lifestyles. Diseases such as obesity and coronary heart disease will therefore become more prevalent. The neuromodulation devices market in the emerging economies will also benefit from a rise in demand for non-invasive treatment options and medical tourism. Growth in this market will also be driven by the approval and launch of neuromodulation devices that are more effective and involve a more simplified, less-invasive implantation procedure.
Neuromodulation Devices: World Market Prospects 2013-2023 analyses the top 4 companies involved in the neuromodulation devices market. This report also provides sales forecasts, market share analyses, discussions of technological developments and analyses of commercial drivers and restraints, including SWOT analysis of the overall neuromodulation devices market. There are 75 tables and figures included. The result is comprehensive profiles on the leading companies operating in the neuromodulation devices market with detailed analyses and informed opinion to benefit your work. Visiongain has determined that the value of the global Neuromodulation Devices Market will reach $12.45bn in 2023.
What makes this report unique?
Visiongain consulted widely with industry experts and full transcripts from these exclusive interviews are included in the report. As such, our reports have a unique blend of primary and secondary sources providing informed opinion. The report provides insight into key drivers and restraints facing the industry, as well as identifying leading companies. The report also provides a unique blend of qualitative analysis combined with extensive quantitative data including global, submarket and national market forecasts from 2012-2023 – all highlighting key business opportunities.
Why you should buy Neuromodulation Devices: World Market Prospects 2013-2023
• 111 pages of comprehensive analysis
• 2 Exclusive Visiongain interviews with experts from-
– Cochlear Ltd
– a US-based Medical Device Company (views provided anonymously)
• 75 tables, charts, and graphs
• Neuromodulation Device market forecasts between 2012-2023
• 3 Neuromodulation Device submarket forecasts from 2012-2023
– Spinal Cord Stimulation (SCS)
– Deep Brain Stimulation (DBS)
– Vagus Nerve Stimulation (VNS)
• A SWOT analysis
• Several leading companies identified and 4 profiled –
– Medtronic
– St. Jude Medical
– Boston Scientific
– Cyberonics
You can order this report today
Gain an understanding of the overall neuromodulation devices market and the leading companies operating in this market by ordering Neuromodulation Devices: World Market Prospects 2013-2023.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view free sample pages of this report please click here
1. Executive Summary
1.1 Sector Highlights
1.2 Aim, Scope and Format of the Report
1.3 Chapter Outline
1.4 Research and Analysis Method
1.5 Glossary of Terms Related to the Report
2. An Introduction to Neuromodulation
2.1 Neuromodulation
2.2 Techniques Used in Neuromodulation
2.2.1 Electrical Stimulation Techniques
2.2.1.1 Brain and Spinal Cord Therapies
2.2.1.2 Cranial Nerve Stimulation
2.2.1.3 Functional Electrical Stimulation
2.2.2 Pharmacological Therapy
2.3 Application of Neuromodulation
2.3.1 Pain
2.3.1.1 Neuromodulation in The Management of Pain
2.3.2 Depression
2.3.2.1 Neuromodulation in The Management of Depression
2.3.3 Epilepsy
2.3.3.1 Neuromodulation in The Management of Epilepsy
2.3.4 Urological Disorders: Overactive Bladder & Urinary Incontinence
2.3.4.1 Neuromulation in The Management of Urinary Incontinence
2.3.5 Hearing Disorders: Profound Deafness
2.3.5.1 Neuromodulation in The Management of Impaired Hearing
2.3.6 Cardiac Disorders: Arrhythmias & Angina
2.3.6.1 Neuromodulation in The Management of Cardiac Disorders
2.3.7 Parkinson's Disease
2.3.7.1 Neuromodulation in The Management of Parkinson's Disease
3. The Global Neuromodulation Devices Market, 2011-2023
3.1 The Global Medical Device Market, 2011
3.1.1 The Global Neurology Devices Market, 2011
3.2 The Global Neuromodulation Devices Market, 2011
3.3 The Global Neuromodulation Devices Market Forecast, 2013-2023
3.4 Neuromodulation Devices: Industry Trends, 2013-2023
4. Neuromodulation Devices Market Sectors: Spinal Cord Stimulation
4.1 Spinal Cord Stimulation (SCS)
4.2 SCS Market Forecast, 2013-2023
4.3 Spinal Cord Stimulation: Industry Trends, 2013-2023
4.4 Companies and Products
4.4.1 Medtronic
4.4.2 Boston Scientific
4.4.3 St. Jude Medical (SJM)
4.4.4 Nevro
5. Neuromodulation Devices Market Sectors: Deep Brain Stimulation
5.1 Deep Brain Stimulation (DBS)
5.2 DBS Market Forecast, 2013-2023
5.3 Deep Brain Stimulation: Industry Trends, 2013-2023
5.4 Companies and Products
5.4.1 Medtronic
5.4.2 St. Jude Medical
6. Neuromodulation Devices Market Sectors: Vagus Nerve Stimulation
6.1 Vagus Nerve Stimulation (VNS)
6.2 VNS Market Forecast, 2013-2023
6.3 Vagus Nerve Stimulation: Industry Trends, 2013-2023
6.4 Companies and Products
6.4.1 Cyberonics
6.4.2 CerebralRx (a spin-off of BioControl Medical)
6.4.3 EnteroMedics
7. The Leading Neuromodulation Device Manufacturers, 2011
7.1 Few Players Dominate the Market
7.2 Neuromodulation Device Market: Breakdown By Company, 2011
7.3 Medtronic
7.3.1 Sales and Recent Performance Analysis, 2011
7.3.1.1 Restorative Therapies
7.3.2 Medtronic Geographic Sales
7.3.3 Medtronic News
7.3.3.1 Expanding Into Sacral Neuromodulation
7.3.3.2 Adaptive Spinal Neuromodulation
7.4 St. Jude Medical (SJM)
7.4.1 Sales and Recent Performance Analysis, 2011
7.4.1.1 Cardiac Rhythm Management/Neuromodulation (CRM/NMD)
7.4.2 SJM Geographic Sales
7.4.3 SJM News
7.4.3.1 Peripheral Nerve Stimulation (PNS)
7.5 Boston Scientific
7.5.1 Sales and Recent Performance Analysis, 2011
7.5.2 Boston Scientific Geographic Sales
7.5.3 Boston Scientific News
7.5.3.1 Advancements in Deep Brain Stimulation (DBS) Technology
7.6 Cyberonics
7.6.1 Sales and Recent Performance Analysis, 2011
7.6.2 Cyberonics Geographic Sales
7.6.3 Cyberonics News
7.6.3.1 Strengthening VNS Technology Through Investment
7.7 Other Neuromodulation Device Manufacturers
8. Leading National Neuromodulation Devices Market, 2013-2023
8.1 Regional Breakdown of The Global Neuromodulation Devices Market, 2011
8.2 The Global Neuromodulation Devices Market: Regional Forecast, 2011-2023
8.3 The US Market
8.4 The European Market
8.4.1 Germany
8.4.2 France
8.4.3 Italy
8.4.4 Spain
8.4.5 UK
8.5 The Japanese Market
8.6 The Chinese Market
8.7 The Indian Market
9. Neuromodulation Devices Market: Industry Pipeline
9.1 Innovative Technology Drives the Market
9.2 Apnex Medical
9.3 CVRx
9.4 EnteroMedics
9.5 ImThera Medical
9.6 Intelect Medical (acquired by Boston Scientific Corporation)
9.7 MetaCure
9.8 NeuroPace
10. SWOT Analysis of The Neuromodulation Devices Market, 2011
10.1 Neuromodulation Devices: Industry Trends
10.2 Strengths
10.2.1 Safer Alternative
10.2.2 Cost Effective
10.2.3 Less Medication
10.3 Weaknesses
10.3.1 Mechanisms Are Not Well Understood
10.3.2 Market Dominated by Small Number of Large Companies
10.3.3 FDA Approvals
10.3.4 Failing Clinical Trials
10.4 Opportunities
10.4.1 Expanding Disease Indications
10.4.2 Increasing Prevalence of Neurological Diseases
10.4.3 The Potential of Personalised Medicine
10.4.4 Expansion into Emerging Markets
10.5 Threats
10.5.1 Emergence of Stem Cells
10.5.2 SCS Faces Competition from Other Treatment Options
10.5.3 Increasing Regulatory Scrutiny
11. Opinions from Our Industry Survey
11.1 Interview with Spokesperson From Medical Device Company
11.1.1 The Cochlear Implant Market
11.1.2 Cochlear Implant Technology
11.1.3 Products and Competition
11.1.4 Future Cochlear Implant Market
11.2 Interview with Mr. Martin Dobelle, Avery Biomedical
11.2.1 The Neuromodulation Devices Market
11.2.2 Phrenic Nerve Stimulation & The Breathing Pacemaker System
11.2.3 Patient Perception and Regulation
11.2.4 Future Projections for The Neuromodulation Devices Market
12. Conclusions
12.1 Overview
12.2 Spinal Cord Stimulation will Remain the Largest Segment
12.3 Prominent Companies in The Market
12.4 World Market Forecasts
12.5 Future Outlook and Concluding Remarks
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 3.1 Net Sales ($bn) and Market Shares (%) Of The Global Medical Market, By Sector, 2011
Table 3.2 The Global Neurology Devices Market: Net Sales ($bn) and Market Shares (%), By Speciality, 2011
Table 3.3 The Global Neuromodulation Devices Market: Net Sales ($bn) and Market Shares (%), By Technology, 2011
Table 3.4 The Global Neuromodulation Devices Market Forecast, By Sector ($bn), 2011-2017
Table 3.5 The Global Neuromodulation Devices Market Forecast, By Sector ($bn), 2017-2023
Table 4.1 Spinal Cord Stimulation: Market Forecast ($bn), 2011-2017
Table 4.2 Spinal Cord Stimulation: Market Forecast ($bn), 2017-2023
Table 5.1 Deep Brain Stimulation: Market Forecast ($bn), 2011-2017
Table 5.2 Deep Brain Stimulation: Market Forecast ($bn), 2017-2023
Table 6.1 Vagus Nerve Stimulation: Market Forecast ($bn), 2011-2017
Table 6.2 Vagus Nerve Stimulation: Market Forecast ($bn), 2017-2023
Table 7.1 Neuromodulation Devices: Net Sales ($bn) and Market Shares (%), By Company, 2011
Table 7.2 Medtronic: Net Sales ($bn) and Market Shares (%), By Segment, 2011
Table 7.3 Restorative Therapies: Net Sales ($bn) and Market Shares (%), By Product Line, 2011
Table 7.4 Medtronic: Net Sales ($bn) and Market Shares (%), By Region, 2011
Table 7.5 SJM: Net Sales ($bn) and Market Shares (%), By Segment, 2011
Table 7.6 CRM/NMD Segment: Net Sales ($bn) and Market Shares (%), By Product Group, 2011
Table 7.7 SJM: Net Sales ($bn) and Market Shares (%), By Region, 2011
Table 7.8 Boston Scientific: Net Sales ($bn) and Market Shares (%), By Product Category, 2011
Table 7.9 Boston Scientific: Net Sales ($bn) and Market Shares (%), By Region, 2011
Table 7.10 Cyberonics: Net Sales ($m) and Market Shares (%), By Region, 2011
Table 7.11 Other Companies Operating in The Global Neuromodulation Device Market, 2012
Table 8.1 Neuromodulation Devices: Sales ($bn) and Market Shares (%), By Country/Region, 2011
Table 8.2 Neuromodulation Devices Market Forecast ($bn), By Country/Region, 2011-2023
Table 8.3 The Leading European Neuromodulation Devices Markets: Market Value ($bn), European Market Shares (%) and Global Market Shares (%), By Region, 2011
Table 8.4 The European Neuromodulation Devices Market Forecast ($bn), By Region, 2011-2023
Table 9.1 Neuromodulation Devices: Industry Pipeline, 2012
Table 10.1 SWOT Analysis of the Neuromodulation Devices Market, 2012
Table 12.1 Neuromodulation Devices Market Forecast ($bn) By Technology, in 2017, 2019 and 2023
List of Figures
Figure 3.1 Market Shares (%) Of The Global Medical Device Market, By Sector, 2011
Figure 3.2 The Global Neurology Devices Market: Market Shares (%), By Speciality, 2011
Figure 3.3 The Global Neuromodulation Devices Market: Net Sales ($bn), By Technology, 2011
Figure 3.4 The Global Neuromodulation Devices Market: Market Shares (%), By Technology, 2011
Figure 3.5 The Global Neuromodulation Devices Market Forecast, 2011-2017
Figure 3.6 The Global Neuromodulation Devices Market Forecast, 2017-2023
Figure 4.1 Spinal Cord Stimulation: Market Forecast ($bn), 2011-2017
Figure 4.2 Spinal Cord Stimulation: Market Forecast ($bn), 2017-2023
Figure 5.1 Deep Brain Stimulation: Market Forecast ($bn), 2011-2017
Figure 5.2 Deep Brain Stimulation: Market Forecast ($bn), 2017-2023
Figure 6.1 Vagus Nerve Stimulation: Market Forecast ($bn), 2011-2017
Figure 6.2 Vagus Nerve Stimulation: Market Forecast ($bn), 2017-2023
Figure 7.1 Neuromodulation Devices: Net Sales ($bn), By Company, 2011
Figure 7.2 Neuromodulation Devices: Market Shares (%), By Company, 2011
Figure 7.3 Medtronic: Market Shares (%), By Segment, 2011
Figure 7.4 Restorative Therapies: Net Sales ($bn), By Product Line, 2011
Figure 7.5 Restorative Therapies: Market Shares (%), By Product Line, 2011
Figure 7.6 Medtronic: Net Sales ($bn), By Region, 2011
Figure 7.7 Medtronic: Market Shares (%), By Region, 2011
Figure 7.8 SJM: Market Shares (%), By Segment, 2011
Figure 7.9 CRM/NMD Segment: Market Shares (%), By Product Group, 2011
Figure 7.10 SJM: Net Sales ($bn), By Region, 2011
Figure 7.11 SJM: Market Shares (%), By Region, 2011
Figure 7.12 Boston Scientific: Net Sales ($bn), By Product Category, 2011
Figure 7.13 Boston Scientific: Market Shares (%), By Product Category, 2011
Figure 7.14 Boston Scientific: Net Sales ($bn), By Region, 2011
Figure 7.15 Boston Scientific: Market Shares (%), By Region, 2011
Figure 7.16 Cyberonics: Net Sales ($m), By Quarter, 2011
Figure 7.17 Cyberonics: Net Sales ($m), By Region, 2011
Figure 7.18 Cyberonics: Market Shares (%), By Region, 2011
Figure 8.1 Neuromodulation Devices: Net Sales ($bn), By Region, 2011
Figure 8.2 Neuromodulation Devices: Market Shares (%), By Region, 2011
Figure 8.3 The US Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.4 The European Neuromodulation Devices Market: Net Sales ($bn), By Region, 2011
Figure 8.5 The European Neuromodulation Devices Market: Market Shares (%), By Region, 2011
Figure 8.6 The European Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.7 The German Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.8 The French Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.9 The Italian Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.10 The Spanish Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.11 The UK Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.12 The Japanese Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.13 The Chinese Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 8.14 The Indian Neuromodulation Devices Market Forecast ($bn), 2011-2023
Figure 12.1 Projected Neuromodulation Devices Market Size for 2017, 2019 and 2023, By Technology
Figure 12.2 Projected Total Neuromodulation Devices Market Size ($bn) in 2011, 2017, 2019 and 2023
To view free sample pages of this report please click here
Advanced Bionics
Aleva Neurotherapeutics
Apnex Medical
Atrotech
Autonomic Technologies
Avery Biomedical
BioControl Medical
Boston Scientific
Cerbomed
Cervel Neurotech
CVRx
Cyberonics
ElectroCore
EnteroMedics
Functional Neuromodulation
ImThera Medical
Inspire Medical Systems
Intelect Medical
IntraPace
Med-El
Medtronic
MetaCure
MicroTransponder
Neurelec
Neuronetics
Neuronix Medical
NeuroPace
Neuros Medical
Neurosigma
Neurotech Group
Neurowave Medical Technologies
Nevro
Respicardia
Retina Implant AG
RS Medical/Vertis Neuroscience
Second Sight Medical Products
Spinal Modulation
SPR Therapeutics
St. Jude Medical
Synapse Biomedical
Uroplasty
Government Agencies and Other Organisations Mentioned in This Report
FDA
WHO
UN
EU
To view free sample pages of this report please click here
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
